Madiha Derouazi
Hoofd Techniek/Wetenschap/O&O bij AC IMMUNE SA
Vermogen: 14 764 $ op 31-05-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Andrea Pfeifer | M | 66 | 21 jaar | |
| Douglas Williams | M | 66 | 6 jaar | |
| Oliver Sol | M | 58 | 8 jaar | |
| Gary Waanders | M | 60 | - | |
| Carl June | M | 70 | 4 jaar | |
| Werner Lanthaler | M | 56 | 6 jaar | |
| Jean-Fabien Monin | M | 54 | 15 jaar | |
| Christopher Roberts | M | 35 | 5 jaar | |
| Monika Bütler | M | 63 | 3 jaar | |
| Piergiorgio Donati | M | 54 | 6 jaar | |
| Roy Ervin Twyman | M | 68 | 5 jaar | |
| Monica Shaw | M | 46 | 3 jaar | |
| Johanna Holldack | M | - |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Howard Donovan | M | 49 | 2 jaar | |
| Julian Snow | M | - | - | |
| Mark Danton | M | 60 | 5 jaar | |
| Andreas Wallnöfer | M | 63 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Bojana Portmann | M | 43 | 13 jaar | |
| Julien Rongère | M | 47 | 7 jaar | |
| Alexandre Caratsch | M | 59 | 6 jaar | |
| Frank Kalkbrenner | M | - |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Sonia Maria Poli | M | 59 | 7 jaar | |
| Karin Hehenberger | M | 52 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Nuno Mendonça | M | 42 | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Marie Kosco-Vilbois | M | 67 | 5 jaar | |
| Roberto de Ponti | M | - |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | 1 jaar |
| Laurence de Schoulepnikoff | F | - |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Zwitserland | 27 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Madiha Derouazi
- Persoonlijk netwerk
